parasympatholytics

Preferred Label : parasympatholytics;

MeSH definition : Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS.;

MeSH synonym : agents, parasympathetic-blocking; agents, parasympatholytic; parasympatholytic agents; parasympathetic-blocking agents; drugs, parasympatholytic; parasympatholytic drugs; parasympathetic blocking agents; Parasympatholytic Agent; Agent, Parasympatholytic; Parasympatholytic Drug; Drug, Parasympatholytic; Parasympatholytic; Parasympathetic-Blocking Agent; Agent, Parasympathetic-Blocking; Parasympathetic Blocking Agent;

Related MeSH term : antispasmodic effect; antispasmodics; parasympatholytic effect; Effect, Parasympatholytic; Parasympatholytic Effects; Effects, Parasympatholytic; Effect, Antispasmodic; Antispasmodic Effects; Effects, Antispasmodic; Antispasmodic Drugs; Drugs, Antispasmodic; Spasmolytics; Antispasmodic Agents; Agents, Antispasmodic; Antispasmodic Drug; Drug, Antispasmodic; Spasmolytic; Antispasmodic; Antispasmodic Agent; Agent, Antispasmodic;

MeSH annotation : note entry term PARASYMPATHOLYTIC EFFECT: use only for the parasympatholyic effect of a chemical substance;

Wikipedia link : https://en.wikipedia.org/wiki/Spasmolytic;

Is substance : O;

action pharmacologique : O;

Details

Origin ID

D010276;

UMLS CUI

C0030511;

ATC code(s)
- mebeverine [ATC Code]
ATC code(s)
- antacids with antispasmodics [ATC Code]
- antispasmodics and anticholinergics in combination with other drugs [ATC Code]
- antispasmodics in combination with analgesics [ATC Code]
- antispasmodics in combination with other drugs [ATC Code]
- antispasmodics in combination with psycholeptics [ATC Code]
- antispasmodics, psycholeptics and analgesics in combination [ATC Code]
- hydromorphone and antispasmodics [ATC Code]
- ketobemidone and antispasmodics [ATC Code]
- morphine and antispasmodics [ATC Code]
- opioids in combination with antispasmodics [ATC Code]
- other antispasmodics in combination with analgesics [ATC Code]
- pethidine and antispasmodics [ATC Code]
- pinaverium [ATC Code]
- proxazole [ATC Code]
- synthetic antispasmodics, amides with tertiary amines [ATC Code]
- urologicals [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Antispasmodic (substance) [SNOMED CT concept]
- Antispasmodic Agent [NCIt concept]
- Parasympatholytic [ICHI extension code]
- Product containing acetylcholine receptor antagonist (product) [SNOMED CT concept]
- Substance with acetylcholine receptor antagonist mechanism of action (substance) [SNOMED CT concept]
- anticholinergic agent, nos [SNOMED Notion]
- antispasmodic [Radlex concept]
- antispasmodic, nos [SNOMED Notion]
CISMeF manual mappings
- Parasympatholytic poisoning (disorder) [SNOMED CT concept]
Currated CISMeF NLP mapping
- Parasympatholytic [ICD-11 Extension code]
Indexing information
- 3,4'-dihydroxy-5,5'-dimethoxybibenzyl [MeSH Supplementary Concept]
- cyclotropium [MeSH Supplementary Concept]
- diprosine [MeSH Supplementary Concept]
- galetin 3,6-dimethyl ether [MeSH Supplementary Concept]
- myrsigenin [MeSH Supplementary Concept]
- pancreatic spasmolytic polypeptide [MeSH Supplementary Concept]
Record concept(s)
- antispasmodic effect [MeSH concept]
- antispasmodics [MeSH concept]
- parasympatholytic effect [MeSH concept]
- parasympatholytics [MeSH concept]
See also
- anti-ulcer agents [MeSH Descriptor]
- antiparkinson agents [MeSH Descriptor]
- muscarinic antagonists [MeSH Descriptor]
- muscle relaxants, central [MeSH Descriptor]
- parasympathetic nervous system [MeSH Descriptor]
- solanaceous alkaloids [MeSH Descriptor]
See also (suggested by CISMeF)
- spasm [MeSH Descriptor]
See also inter- (CISMeF)
- Antispasticity drugs [Bloc CIM-11]
- Medicinal product acting as antispasmodic agent (product) [SNOMED CT concept]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- 1,3,5-trimethoxybenzene [MeSH Supplementary Concept]
- 4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide [MeSH Supplementary Concept]
- 4-diphenylacetoxy-1,1-dimethylpiperidinium [MeSH Supplementary Concept]
- 4-fluorohexahydrosiladifenidol [MeSH Supplementary Concept]
- AFDX 384 [MeSH Supplementary Concept]
- N-methylscopolamine [MeSH Descriptor]
- Tiotropium Bromide [MeSH Descriptor]
- alrestatin [MeSH Supplementary Concept]
- alverine [MeSH Supplementary Concept]
- anisodamine [MeSH Supplementary Concept]
- anisodine [MeSH Supplementary Concept]
- aprofen [MeSH Supplementary Concept]
- atropine [MeSH Descriptor]
- benactyzine [MeSH Descriptor]
- benztropine [MeSH Descriptor]
- biperiden [MeSH Descriptor]
- biperiden lactate [MeSH Supplementary Concept]
- butylscopolammonium bromide [MeSH Descriptor]
- camylofine [MeSH Supplementary Concept]
- cimetropium [MeSH Supplementary Concept]
- clidinium [MeSH Supplementary Concept]
- cromakalim [MeSH Descriptor]
- cyclopentolate [MeSH Descriptor]
- dexetimide [MeSH Descriptor]
- dicyclomine [MeSH Descriptor]
- diphemanil methylsulfate [MeSH Supplementary Concept]
- drotaverin [MeSH Supplementary Concept]
- emepronium [MeSH Descriptor]
- emepronium carrageenate [MeSH Supplementary Concept]
- enpiperate [MeSH Supplementary Concept]
- eperisone [MeSH Supplementary Concept]
- ethaverine [MeSH Supplementary Concept]
- falipamil [MeSH Supplementary Concept]
- fenoverine [MeSH Supplementary Concept]
- fenpiverinium bromide, pitofenone hydrochloride, dipyrone drug combination [MeSH Supplementary Concept]
- flavoxate [MeSH Descriptor]
- ganglerone [MeSH Supplementary Concept]
- glaucine [MeSH Supplementary Concept]
- hexahydrosiladifenidol [MeSH Supplementary Concept]
- himbacine [MeSH Supplementary Concept]
- homatropine [MeSH Supplementary Concept]
- hydroquinidine [MeSH Supplementary Concept]
- hyoscyamine [MeSH Descriptor]
- mebeverine [MeSH Supplementary Concept]
- methoctramine [MeSH Supplementary Concept]
- methylatropine [MeSH Supplementary Concept]
- moxaverine [MeSH Supplementary Concept]
- octylonium [MeSH Supplementary Concept]
- orphenadrine [MeSH Descriptor]
- otenzepad [MeSH Supplementary Concept]
- oxitropium [MeSH Supplementary Concept]
- oxybutynin [MeSH Supplementary Concept]
- oxyphenonium [MeSH Descriptor]
- peppermint oil [MeSH Supplementary Concept]
- perhydrohistrionicotoxin [MeSH Supplementary Concept]
- pinaverium [MeSH Supplementary Concept]
- propiverine [MeSH Supplementary Concept]
- rociverine [MeSH Supplementary Concept]
- secoverine [MeSH Supplementary Concept]
- telenzepine [MeSH Supplementary Concept]
- terodiline [MeSH Supplementary Concept]
- tiropramide [MeSH Supplementary Concept]
- tizanidine [MeSH Supplementary Concept]
- trimebutine [MeSH Descriptor]
- trospium chloride [MeSH Supplementary Concept]
- zetidoline [MeSH Supplementary Concept]
UMLS correspondences (same concept)
- Parasympatholytic [ICD-11 Extension code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients